Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study

Abstract

Serum VEGF level at 6 months post treatment is a predicative biomarker for disease activity and prognosis in POEMS syndrome. Serum VEGF could be used as a surrogate endpoint for relapse-free survival or clinical or laboratory improvement of POEMS syndrome for clinical trials.